US Patent

US9738625 — Therapeutically active compounds and their methods of use

Composition of Matter · Assigned to Agios Pharmaceuticals Inc · Expires 2034-08-01 · 8y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects IDH2 inhibitor compounds, including their polymorphic forms, for treating cancer.

USPTO Abstract

Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.

Drugs covered by this patent

Patent Metadata

Patent number
US9738625
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-08-01
Drug substance claim
Yes
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.